(NASDAQ: BRNS) Barinthus Biotherapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 19.09%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 27.19%.
Barinthus Biotherapeutics's earnings in 2025 is -$57,827,000.On average, 2 Wall Street analysts forecast BRNS's earnings for 2025 to be -$52,498,135, with the lowest BRNS earnings forecast at -$61,147,253, and the highest BRNS earnings forecast at -$43,849,017. On average, 1 Wall Street analyst forecast BRNS's earnings for 2026 to be -$68,388,375, with the lowest BRNS earnings forecast at -$68,388,375, and the highest BRNS earnings forecast at -$68,388,375.
In 2027, BRNS is forecast to generate -$121,489,937 in earnings, with the lowest earnings forecast at -$121,489,937 and the highest earnings forecast at -$121,489,937.